Recruiting
Phase 2

Rituximab vs. Mosunetuzumab

Sponsor:

National Cancer Institute (NCI)

Code:

NCT05886036

Conditions

Nodular Lymphocyte Predominant B-Cell Lymphoma

Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma

Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biopsy Procedure

Biospecimen Collection

Bone Marrow Biopsy

Computed Tomography

Fludeoxyglucose F-18

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-20. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2025-05-22.